Patient/caregiver perceived benefits and barriers to elective orthopedic surgery (EOS) in patients with congenital hemophilia with inhibitors

References

• Soucie JM, Evatt, B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-94
   Google Scholar
• World Federation of Hemophilia. Guidelines for the management of hemophilia. World Federation of Hemophilia; 2005
   Google Scholar
• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-9
   PubMed Web of Science ®Google Scholar
• Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005;11(1 Suppl):11-17
   PubMedGoogle Scholar
• Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilia arthropathy. J Thomb Haemost 2010;8:1895-902
   PubMed Web of Science ®Google Scholar
• Zakarija A, Harris S, Rademaker AW, et al. Alloantibodies to factor VIII in haemophilia. Haemophilia 2011; doi: 10.1111/j.1365-2516.2010.02468.x. [Epub ahead of print]
   PubMedGoogle Scholar
• Boadas A, Fernandez-Palazzi F, DE Bosch NB, et al. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela. Haemophilia 2010; doi 10.1111/j.1365-2516.2010.02427.x. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011; doi: 10.1111/j.1365-2516.2010.02460.x. [Epub ahead of print]
   Google Scholar
• Giangrande PLF, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [Eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009;15:501-8
   PubMed Web of Science ®Google Scholar
• Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Thromb Haemost 2007;98:726-32
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-8
   PubMed Web of Science ®Google Scholar
• NovoSeven® RT [Package insert]. Princeton, NJ: Novo Nordisk Inc, 2010
   Google Scholar
• Bysted BV, Scharling B, Moller T, et al. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia 2007:13:527-32
   PubMed Web of Science ®Google Scholar
• Ludlam C. Identifying and managing inhibitor patients requiring orthopaedic surgery – the multidisciplinary team approach. Haemophilia 2005;11(1 Suppl):7-10
   PubMedGoogle Scholar
• Teitel JM, Carcao M, Lillicrap D, et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009;15:227-39
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007;25:1007-29
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Manco-Johnson MJ. Meeting unmet needs in inhibitor patients. Haemophilia 2010;1(3 Suppl):46-51
   Google Scholar
• Rodriguez-Merchan EC, Wiedel JD, Wallny T, et al. Elective orthopedic surgery for hemophilia patients with inhibitors: new opportunities. Semin Hematol 2004;41(1 Suppl):109-16
   PubMed Web of Science ®Google Scholar
• Hvid I, Rodriguez-Merchan EC. Orthopedic surgery in hemophilia patients with inhibitors: an overview. Haemophilia 2002;8:288-91
   PubMed Web of Science ®Google Scholar
• Miners AH, Sabin CA, Tolley KH, et al. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med. 2000;247:493-499.
   Google Scholar
• Ballal RD, Botteman MF, Stephens JM, et al. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin. 2008 Mar;24(3):753-68.
   PubMed Web of Science ®Google Scholar
• Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, et al. Controversies and challenges in elective orthopedic surgery in patients with hemophilia with inhibitors. Semin Hematol. 2008 Apr;45(2 Suppl 1):S64-7.
   PubMed Web of Science ®Google Scholar
• Caviglia H, Candela M, Galatro G, et al. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature. Haemophilia. 2011 Feb 22. doi: 10.1111/j.1365-2516.2011.02504.x. [Epub ahead of print]
   Google Scholar
• Centers for Disease Control and Prevention – Universal Data Collection (UDC) System, Available at http://www.cdc.gov/ncbddd/blooddisorders/udc [Last accessed 19 August 2011]
   Google Scholar